HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Del Labs Realigns Under New CEO Hinkaty As McMenemy Steps Down

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Del Labs Chief Operating Officer Charles Hinkaty will take the helm as president and CEO of the company effective Aug. 19, succeeding William McMenemy, who is retiring, the firm reported Aug. 15

You may also be interested in...



Sally Hansen Unveils Anti-Aging Regimen For Hands

Sally Hansen Advanced Hand Treatments will launch in January as the brand's first complete line of anti-aging hand care products, Del Labs announced

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Table

View full table

Tags:
Latest Headlines

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer

Over The Counter 22 Apr 2024: Helping Consumers ‘Tune In’ To Reliable Health Information, With Kaizo PR's Anita Nahal

See All
UsernamePublicRestriction

Register

RS013285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By